摘要To The Editor:Bariatric surgery,as an effective treatment for patients with morbid obesity and its related metabolic diseases,is gaining increasing popularity.Non-alcoholic fatty liver disease (NAFLD) is a common comorbidity associated with morbid obesity.Growing evidence suggests that patients with non-alcoholic steatohepatitis are at high-risk of adverse outcomes such as cirrhosis and liver-related mortality.Liver function failure caused by NAFLD is predicted to become the most common reason for liver transplantation (LT) in the United States by 2025.[1] The estmated prevalence of obesity is 20％ to 30％ in LT recipients in the United States.[2] LT is the only radical treatment for end-stage liver disease.If patients with end-stage liver disease and morbid obesity cannot effectively control their body weight after LT,the donor liver will be at high-risk of NAFLD again.